Regulatory status

Retatrutide FDA approval status

What the FDA record actually shows, what Lilly has said, and the specific steps that separate the two.

By Evan Marsh · Updated

Retatrutide is not FDA approved. It is an investigational drug with no approval record in Drugs@FDA. Lilly says it plans to submit a Biologics License Application in Q1 2027. A submission would begin the regulatory process; it would not itself make retatrutide an approved medicine.

Verified against Drugs@FDAand Lilly's 23 July 2026 releaseon 30 July 2026.

Monitoring activeLast verified

Not FDA approved

Retatrutide remains an investigational drug. It has not been approved by the FDA or by any other regulator, and no FDA decision date has been announced. Lilly has said it plans to submit a Biologics License Application in Q1 2027. A submission would begin the regulatory process; it would not itself make retatrutide an approved medicine.

Regulatory status
Investigational
Approval date
None. No FDA decision date exists.
Planned BLA submission
Q1 2027 (company projection)

Submission is not approval. Filing a Biologics License Application asks the FDA to begin a review. The FDA can accept it, refuse to file it, approve the drug, or issue a complete response letter instead.What has to happen before approval.

Primary source:Drugs@FDA: FDA-Approved Drugs,U.S. Food and Drug Administration. Checked July 30, 2026.

What “investigational” means

Investigational is not a marketing adjective. It is the FDA's classification for a drug being studied under an Investigational New Drug application. A drug in that category may be given to people inside authorised clinical research, and may not be sold, prescribed or advertised as a treatment.

Retatrutide entered that category in 2019 with its first human study and has not left it. Nothing Lilly has announced — not five positive Phase 3 readouts, not a stated filing plan — changes it. Only the FDA can, and only after an application is filed, reviewed and approved.

The steps between here and approval

These are distinct regulatory events. Conflating them is the most common error in coverage of drugs at this stage, and it is usually what turns a plan into a promise. None of the four has happened.

1. Submission of a Biologics License Application

A BLA is the filing through which a sponsor asks the FDA to license a biological product. It contains the clinical data, the safety database, and the Chemistry, Manufacturing and Controls package documenting how the drug is made and kept consistent. Lilly stated on 23 July 2026 that it is completing that CMC package and “plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.”

Status: not done. The date is the company's own projection. Filing dates commonly move, and the manufacturing package is one of the more common reasons they do.

2. FDA filing decision

After a submission, the FDA has roughly 60 days to decide whether the application is complete enough to review. If it is, the agency files the application and the review clock starts. If it is not, the agency issues a Refuse to File letter and the sponsor has to fix and resubmit.

Acceptance is not approval. It is the FDA saying the paperwork is reviewable, nothing more. This distinction gets lost constantly, because “FDA accepts application” reads like good news and is reported as though it were a decision on the drug.

3. A PDUFA date is assigned

On filing, the FDA sets a target date for completing its review under the Prescription Drug User Fee Act. Standard review is about ten months from filing; priority review is about six. The PDUFA date is a goal for the agency, not a guarantee, and the FDA can and does miss it.

No PDUFA date exists for retatrutide, and none can until an application is submitted and accepted. Any date presented today as a retatrutide PDUFA date is fabricated.

4. The FDA decides

The review ends one of two ways. An approval means the drug can be marketed for the indications on the approved label. A Complete Response Letter means it cannot, and sets out what the FDA would need — more data, a manufacturing fix, a labelling change, sometimes another trial. Along the way there may be an advisory committee meeting and inspections of manufacturing sites.

Lilly's own forward-looking-statements language on the 23 July 2026 release notes that there is no guarantee retatrutide will receive regulatory approval. That is standard legal text, and it is also simply true.

Definitions

BLA — Biologics License Application
The application asking the FDA to license a biological product for marketing. Submitting it starts the process.
Filing acceptance
The FDA's decision, roughly 60 days after submission, that an application is complete enough to review. Not a decision about the drug.
PDUFA date
The target date by which the FDA aims to complete its review, assigned when an application is filed. Approximately ten months for standard review, six for priority review.
CRL — Complete Response Letter
The FDA's response when it will not approve an application in its current form, setting out what would have to change.
Expanded access
A regulated pathway through which a patient may receive an investigational drug outside a trial, requiring the sponsor's agreement, a treating physician and FDA authorisation. Not a prescription.

What remains unknown

It is worth being explicit about the size of the gap, because the confident tone of most coverage hides it. Nobody outside Lilly and the FDA knows whether the Q1 2027 filing will happen on time. Nobody knows whether the FDA will accept it, what indications it would cover, what the label would say about the discontinuation and dysesthesia rates seen in the trials, or whether an advisory committee will be convened. Nobody knows the price, the brand name, or the launch date.

What is knowable is the record, and the record is checked here against the FDA's own database. When it changes, this page changes.

What is confirmed, and what is not

Confirmed

  • Retatrutide is investigational. It has no approval record in Drugs@FDA.
  • Lilly has disclosed positive topline results from five Phase 3 studies.
  • One of those five, TRANSCEND-T2D-1, has been published in a peer-reviewed journal.
  • Lilly has stated it plans to submit a BLA to the FDA in Q1 2027.

Not confirmed

  • That a submission has been made — as of the last check, it has not.
  • Any FDA approval date.
  • Any FDA decision (PDUFA) date.
  • A commercial launch date.
  • A U.S. brand name.
  • A U.S. list price.
  • Insurance or Medicare coverage.

Questions

Has retatrutide been submitted to the FDA?

No. As of the last verification date, no application for retatrutide has been submitted to the FDA. Lilly has stated that it plans to submit a Biologics License Application in Q1 2027.

What is a BLA?

A Biologics License Application is the filing through which a sponsor asks the FDA to license a biological product for marketing. Submitting one begins the regulatory process; it does not conclude it.

Is Q1 2027 the FDA approval date for retatrutide?

No. Q1 2027 is the window in which Lilly says it plans to file its application. It is a company projection about submission, not a date set by the FDA, and not an approval date.

Does a PDUFA date exist for retatrutide?

No. A PDUFA date is assigned only after the FDA accepts an application for review. Since no application has been submitted, no PDUFA date can exist.